@mcw44.bsky.social
As both a parent and a leader, I know firsthand the joys and challenges of balancing family and work. I believe these experiences deserve recognition, support, and celebration, and I I am grateful that @Alltrna fosters such opportunities to learn from each other and grow together.
Behind every breakthrough at Alltrna are people who are not only scientists, innovators, and colleagues, but also parents and caregivers. For Working Parent Awareness Day, our Culture Team hosted an excellent panel about balancing family life with meaningful work.
#NationalWorkingParentsDay
#NationalWorkingParentsDay
October 7, 2025 at 1:05 PM
As both a parent and a leader, I know firsthand the joys and challenges of balancing family and work. I believe these experiences deserve recognition, support, and celebration, and I I am grateful that @Alltrna fosters such opportunities to learn from each other and grow together.
Reposted
95% of genetic #rarediseases lack therapies. On #InternationalPodcastDay, Alltrna CEO @mcw44.bsky.social shares how engineered #tRNA medicines can restore protein production and uniquely treat many diseases with the same underlying mutation.
bit.ly/3VR6LXd
#RNAsky #StopCodonDisease
bit.ly/3VR6LXd
#RNAsky #StopCodonDisease
September 30, 2025 at 2:32 PM
95% of genetic #rarediseases lack therapies. On #InternationalPodcastDay, Alltrna CEO @mcw44.bsky.social shares how engineered #tRNA medicines can restore protein production and uniquely treat many diseases with the same underlying mutation.
bit.ly/3VR6LXd
#RNAsky #StopCodonDisease
bit.ly/3VR6LXd
#RNAsky #StopCodonDisease
The first 25 years of @Flagship Pioneering have proven the power of bold ideas to change medicine. The next 25 are about Bigger Leaps—taking on the greatest challenges in science so that no patient, with a rare or common disease, is left without the chance at a breakthrough.
Congrats to our colleagues at Flagship Pioneering on 25 years of turning bold ideas into medicines. At Alltrna, we’re building on this legacy of #BiggerLeaps by pioneering #tRNA medicines to unify treatment across #StopCodonDisease and redefine what’s possible for patients.
#FlagshipFounded
#FlagshipFounded
September 25, 2025 at 5:19 PM
The first 25 years of @Flagship Pioneering have proven the power of bold ideas to change medicine. The next 25 are about Bigger Leaps—taking on the greatest challenges in science so that no patient, with a rare or common disease, is left without the chance at a breakthrough.
Thanks @Drug Target Review for spotlighting Alltrna’s approach to broadening the reach of genetic medicines. We need to move beyond one-disease, one-drug thinking and #tRNA therapeutics can help us address the severe unmet need in rare and ultra-rare diseases.
#RNAsky
#RNAsky
Drug Target Review spotlights Alltrna’s mutation-driven strategy to expand the reach of genetic medicine. By focusing on the shared genetic cause, rather than one disease at a time, our tRNA therapeutic approach can accelerate rare disease drug development.
bit.ly/4858rUi
#StopCodonDisease
bit.ly/4858rUi
#StopCodonDisease
New tRNA tech aims to rewrite rare disease treatment
Explore the role of tRNA in genetic medicine and how Alltrna is revolutionizing therapies for rare genetic diseases.
www.drugtargetreview.com
September 8, 2025 at 5:01 PM
Proud to work alongside a team that centers accessibility – not as a task, but as a value. We honor #DisabilityPrideMonth by continuing to build a culture where every voice and experience is valued.
#WeAreAlltrna #Inclusion
#WeAreAlltrna #Inclusion
July is #DisabilityPrideMonth, reminding us that disability is a natural and valuable part of human diversity. At Alltrna, accessibility is not a project – it is woven into our values. We are one team, embracing all voices and experiences as we advance tRNA therapeutics for patients.
#WeAreAlltrna
#WeAreAlltrna
July 28, 2025 at 3:28 PM
Proud to work alongside a team that centers accessibility – not as a task, but as a value. We honor #DisabilityPrideMonth by continuing to build a culture where every voice and experience is valued.
#WeAreAlltrna #Inclusion
#WeAreAlltrna #Inclusion
The finale to the conversation I had with Anna Rose Welch! This second article dives into how we’re translating the potential of #tRNA into patient impact—scientifically, strategically, and personally.
Part 2 below.
Part 1 here: bit.ly/3RNGuar
Thanks for following the journey.
#RNAsky
Part 2 below.
Part 1 here: bit.ly/3RNGuar
Thanks for following the journey.
#RNAsky
July 22, 2025 at 7:37 PM
The finale to the conversation I had with Anna Rose Welch! This second article dives into how we’re translating the potential of #tRNA into patient impact—scientifically, strategically, and personally.
Part 2 below.
Part 1 here: bit.ly/3RNGuar
Thanks for following the journey.
#RNAsky
Part 2 below.
Part 1 here: bit.ly/3RNGuar
Thanks for following the journey.
#RNAsky
Thank you for an incredible discussion on next-gen advocacy in rare disease at #BIO2025. Real change takes all of us – patients, families, regulators, industry – pushing forward together.
#RNAsky #rarediseases
#RNAsky #rarediseases
June 19, 2025 at 6:01 PM
Thank you for an incredible discussion on next-gen advocacy in rare disease at #BIO2025. Real change takes all of us – patients, families, regulators, industry – pushing forward together.
#RNAsky #rarediseases
#RNAsky #rarediseases
A special conversation that brings together the personal and the scientific. Thank you, @grinsteinj.bsky.social cial, for the space to share my and @alltrna.bsky.social ial’s story on the 𝘽𝙚𝙝𝙞𝙣𝙙 𝙩𝙝𝙚 𝘽𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙨 podcast.
On Behind the Breakthroughs #podcast, Alltrna CEO @mcw44.bsky.social shares how personal experience drives our mission – and how engineered tRNAs could unlock new treatments for diseases caused by premature stop codons.
Read the Q&A & listen here: bit.ly/4mZWjZN
#tRNA #StopCodonDisease #RNAsky
Read the Q&A & listen here: bit.ly/4mZWjZN
#tRNA #StopCodonDisease #RNAsky
June 12, 2025 at 1:52 PM
A special conversation that brings together the personal and the scientific. Thank you, @grinsteinj.bsky.social cial, for the space to share my and @alltrna.bsky.social ial’s story on the 𝘽𝙚𝙝𝙞𝙣𝙙 𝙩𝙝𝙚 𝘽𝙧𝙚𝙖𝙠𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙨 podcast.
When my son was diagnosed with #Duchenne, patient groups helped me find my way — and today, patients and families continue to inspire my work at @alltrna.bsky.social. In this @Science.org webinar, I share what I learned when my personal and professional journeys converged.
When @mcw44.bsky.social's son was diagnosed with #Duchenne, patient groups became a lifeline. In this @science.org webinar, she shares how that shaped her leadership at Alltrna, listening to families as we develop #tRNA medicines to treat #StopCodonDisease.
www.science.org/content/webi...
#RNAsky
www.science.org/content/webi...
#RNAsky
Bright breakthroughs: Real stories of beating rare disease
www.science.org
June 9, 2025 at 6:12 PM
When my son was diagnosed with #Duchenne, patient groups helped me find my way — and today, patients and families continue to inspire my work at @alltrna.bsky.social. In this @Science.org webinar, I share what I learned when my personal and professional journeys converged.
Advocacy is not just about raising awareness – it’s driving the science forward. I am proud to join incredible voices at #BIO2025 to explore how patients and families are accelerating innovation in rare disease drug development.
Patients and families are driving innovation in rare disease. At #BIO2025, @mcw44.bsky.social joins a panel of champions to explore how next-gen advocacy is accelerating science and transforming how we develop and deliver new medicines.
#RNAsky
#RNAsky
June 3, 2025 at 7:29 PM
Advocacy is not just about raising awareness – it’s driving the science forward. I am proud to join incredible voices at #BIO2025 to explore how patients and families are accelerating innovation in rare disease drug development.
I truly appreciated the opportunity to share my story and our work at @alltrna.bsky.social with @benmcomer.bsky.social, Anna Rose Welch, and Matthew Pillar for the Business of Biotech podcast. Thanks for the great conversation!
A rare disease diagnosis in her own family pushed @mcw44.bsky.social to rethink her career. On the Business of Biotech podcast, she shares what brought her to Alltrna, and why engineered tRNAs may redefine what’s possible in medicine.
🎧 Listen here: www.lifescienceleader.com/doc/leading-...
🎧 Listen here: www.lifescienceleader.com/doc/leading-...
May 29, 2025 at 4:01 PM
I truly appreciated the opportunity to share my story and our work at @alltrna.bsky.social with @benmcomer.bsky.social, Anna Rose Welch, and Matthew Pillar for the Business of Biotech podcast. Thanks for the great conversation!
Reposted
We’ve been walking together this May for #MoveYourPheet, in support of the National PKU Alliance—raising awareness for PKU and connecting as a team. These moments remind us why our work matters. 💚
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #PKUAwarenessMonth #RareDisease
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #PKUAwarenessMonth #RareDisease
May 27, 2025 at 1:33 PM
We’ve been walking together this May for #MoveYourPheet, in support of the National PKU Alliance—raising awareness for PKU and connecting as a team. These moments remind us why our work matters. 💚
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #PKUAwarenessMonth #RareDisease
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #PKUAwarenessMonth #RareDisease
Reposted
𝟵𝟱% 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗵𝗮𝘃𝗲 𝗻𝗼 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝘆. Alltrna’s engineered tRNAs enable a mutation-first approach—and open the door to basket clinical trials across diseases.
@mcw44.bsky.social shares more: bit.ly/3GUXNUx
#ClinicalTrialsDay
@mcw44.bsky.social shares more: bit.ly/3GUXNUx
#ClinicalTrialsDay
Alltrna plans to tackle rare diseases using tRNA-based therapies - Pharmaceutical Technology
Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases together.
bit.ly
May 20, 2025 at 2:43 PM
𝟵𝟱% 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗵𝗮𝘃𝗲 𝗻𝗼 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝘆. Alltrna’s engineered tRNAs enable a mutation-first approach—and open the door to basket clinical trials across diseases.
@mcw44.bsky.social shares more: bit.ly/3GUXNUx
#ClinicalTrialsDay
@mcw44.bsky.social shares more: bit.ly/3GUXNUx
#ClinicalTrialsDay
As a mom to a child with Duchenne, I am especially honored for @alltrna.bsky.social to present at @cureduchenne.bsky.social #FUTURES2025. We are sharing early work on engineered tRNA medicines and their potential to address nonsense mutations in Duchenne.
Alltrna will be at @cureduchenne.bsky.social's #FUTURES2025 to present on how engineered tRNA medicines may uniquely overcome nonsense mutations—also called premature termination codons—in #Duchenne, with the goal of restoring full-length dystrophin.
#StopCodonDisease #RNAsky
#StopCodonDisease #RNAsky
May 15, 2025 at 1:56 PM
As a mom to a child with Duchenne, I am especially honored for @alltrna.bsky.social to present at @cureduchenne.bsky.social #FUTURES2025. We are sharing early work on engineered tRNA medicines and their potential to address nonsense mutations in Duchenne.
Honored to deliver the 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗿𝘁 𝗟𝗲𝗰𝘁𝘂𝗿𝗲 at #ASCPT2025. Being a parent to a child with Duchenne has shaped my belief that empathy and urgency must guide how we transform drug development for rare diseases.
#PatientCentricity #BiotechLeadership
#PatientCentricity #BiotechLeadership
Proud to share that @mcw44.bsky.social is delivering the 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗿𝘁 𝗟𝗲𝗰𝘁𝘂𝗿𝗲 at #ASCPT2025! Her talk will spotlight how empathy and innovation can transform #raredisease #drugdevelopment.
@ascptclinpharm.bsky.social: bit.ly/3F4XyWt
#tRNA #StopCodonDisease #RNAsky #PatientCentricity
@ascptclinpharm.bsky.social: bit.ly/3F4XyWt
#tRNA #StopCodonDisease #RNAsky #PatientCentricity
May 12, 2025 at 2:30 PM
Honored to deliver the 𝗦𝘁𝗮𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗿𝘁 𝗟𝗲𝗰𝘁𝘂𝗿𝗲 at #ASCPT2025. Being a parent to a child with Duchenne has shaped my belief that empathy and urgency must guide how we transform drug development for rare diseases.
#PatientCentricity #BiotechLeadership
#PatientCentricity #BiotechLeadership
Loved this thoughtful—and adventurous—take on the promise of #tRNA. Thank you to Anna Rose Welch for the great conversation and for capturing in Part 1 how we at
@alltrna.bsky.social are unearthing the therapeutic potential of this ancient molecule to build a new future for patients.
@alltrna.bsky.social are unearthing the therapeutic potential of this ancient molecule to build a new future for patients.
𝙍𝙖𝙞𝙙𝙚𝙧𝙨 𝙤𝙛 𝙩𝙝𝙚 𝙇𝙤𝙨𝙩 𝘾𝙤𝙙𝙤𝙣? #tRNA may be ancient, but its therapeutic future is just beginning. In this new article, Alltrna CEO @mcw44.bsky.social shares how we’re using tRNA’s universal biology to potentially treat many diseases.
bit.ly/3RNGuar
#StopCodonDisease #RNAsky
bit.ly/3RNGuar
#StopCodonDisease #RNAsky
"Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics
<p>Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule’s unique “skill set” is gu...
bit.ly
May 7, 2025 at 2:26 PM
Loved this thoughtful—and adventurous—take on the promise of #tRNA. Thank you to Anna Rose Welch for the great conversation and for capturing in Part 1 how we at
@alltrna.bsky.social are unearthing the therapeutic potential of this ancient molecule to build a new future for patients.
@alltrna.bsky.social are unearthing the therapeutic potential of this ancient molecule to build a new future for patients.
Alltrna is proud to support #MoveYourPheet for #PKUAwarenessMonth, an initiative led by the National PKU Alliance. I’m honored to walk alongside this community and to help drive the development of new therapeutics that aim to change the trajectory of PKU and other rare diseases.
It’s #PKUAwarenessMonth, and Alltrna is proud to support #MoveYourPheet, an event benefiting the National PKU Alliance. We’re walking together to raise awareness for PKU and the need for continued innovation in care.
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #RareDisease
Learn more: secure.qgiv.com/event/moveyo...
#PKUAwareness #RareDisease
May 1, 2025 at 3:18 PM
Alltrna is proud to support #MoveYourPheet for #PKUAwarenessMonth, an initiative led by the National PKU Alliance. I’m honored to walk alongside this community and to help drive the development of new therapeutics that aim to change the trajectory of PKU and other rare diseases.
Thank you to @dikaojiakor.bsky.social for covering our work at @alltrna.bsky.social and the promise of AP003—our lead tRNA therapeutic candidate moving toward the clinic.
tRNA is emerging as a powerful new therapeutic approach for #rarediseases. Drug Discovery News highlights how Alltrna is advancing #tRNA medicines to restore protein function across many diseases.
Read the article here: bit.ly/3QYlH3o
#StopCodonDisease
Read the article here: bit.ly/3QYlH3o
#StopCodonDisease
April 22, 2025 at 3:40 PM
Thank you to @dikaojiakor.bsky.social for covering our work at @alltrna.bsky.social and the promise of AP003—our lead tRNA therapeutic candidate moving toward the clinic.
My son’s diagnosis shook my world – but clarified my purpose. As rare disease drug development faces real headwinds, we can’t slow down. We need faster, scalable innovation – and to raise our voices to keep rare disease a priority.
“Every single day matters.”
As FDA layoffs & Priority Review Voucher program uncertainty challenge rare disease drug development, Alltrna CEO @mcw44.bsky.social shares why we need speed, scale & access now more than ever.
Read more in PharmaVoice: bit.ly/3RDgNsO
As FDA layoffs & Priority Review Voucher program uncertainty challenge rare disease drug development, Alltrna CEO @mcw44.bsky.social shares why we need speed, scale & access now more than ever.
Read more in PharmaVoice: bit.ly/3RDgNsO
Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
bit.ly
April 8, 2025 at 4:13 PM
My son’s diagnosis shook my world – but clarified my purpose. As rare disease drug development faces real headwinds, we can’t slow down. We need faster, scalable innovation – and to raise our voices to keep rare disease a priority.
At @alltrna.bsky.social, we’re pioneering a new approach to medicine with tRNA–driven by science and inspired by patients. I shared more about my journey and purpose with BioSpace.
At Alltrna, we believe tRNA is key to unlocking new possibilities in medicine. In this BioSpace feature, our CEO @mcw44.bsky.social shares what drives her–and why our work could build a new future for patients.
bit.ly/3E7SOyX
#tRNA #StopCodonDisease #rarediseases
bit.ly/3E7SOyX
#tRNA #StopCodonDisease #rarediseases
April 7, 2025 at 3:42 PM
At @alltrna.bsky.social, we’re pioneering a new approach to medicine with tRNA–driven by science and inspired by patients. I shared more about my journey and purpose with BioSpace.
Developing personalized medicines is critical for tackling rare diseases, but pursuing a one-drug-per-disease paradigm for the 6,000+ rare genetic conditions is an untenable strategy. Nerissa, Alltrna’s CMO, explains our novel way of addressing this challenge by leveraging tRNA’s unique biology.
What role could tRNAs play in the future of personalized medicine?
Alltrna’s CMO explains that tRNA’s unique biology can be leveraged to develop drugs that are personalized to a patient’s specific mutation but also applicable across many diseases.
Read more at Pharma's Almanac: bit.ly/43eGhUE
Alltrna’s CMO explains that tRNA’s unique biology can be leveraged to develop drugs that are personalized to a patient’s specific mutation but also applicable across many diseases.
Read more at Pharma's Almanac: bit.ly/43eGhUE
March 25, 2025 at 4:41 PM
Developing personalized medicines is critical for tackling rare diseases, but pursuing a one-drug-per-disease paradigm for the 6,000+ rare genetic conditions is an untenable strategy. Nerissa, Alltrna’s CMO, explains our novel way of addressing this challenge by leveraging tRNA’s unique biology.
Reposted
tRNA therapeutics may help restore full-length proteins in muscle #StopCodonDisease. At @mda.org's Annual Conference, Stephen Eichhorn will discuss developing engineered #tRNA therapeutics to address premature termination codons in #rarediseases, like #musculardystrophy.
www.mdaconference.org
www.mdaconference.org
March 17, 2025 at 12:06 PM
tRNA therapeutics may help restore full-length proteins in muscle #StopCodonDisease. At @mda.org's Annual Conference, Stephen Eichhorn will discuss developing engineered #tRNA therapeutics to address premature termination codons in #rarediseases, like #musculardystrophy.
www.mdaconference.org
www.mdaconference.org
Honored to participate in the PPMD 2025 Advocacy Conference, where patients, families, researchers, and policymakers unite to advance progress for #Duchenne. Advocacy plays a key role in shaping policy, driving research, and improving access to treatments for #rarediseases.
bit.ly/41koLvl
bit.ly/41koLvl
March 12, 2025 at 1:19 PM
Honored to participate in the PPMD 2025 Advocacy Conference, where patients, families, researchers, and policymakers unite to advance progress for #Duchenne. Advocacy plays a key role in shaping policy, driving research, and improving access to treatments for #rarediseases.
bit.ly/41koLvl
bit.ly/41koLvl
Rare diseases affect 350M people worldwide, yet 95% have no FDA-approved treatment. We need a bold new approach—and collaboration among all the stakeholders. The time to act is now.
I explain more in this editorial for @fortune.com: fortune.com/2025/03/10/r...
I explain more in this editorial for @fortune.com: fortune.com/2025/03/10/r...
March 10, 2025 at 5:36 PM
Rare diseases affect 350M people worldwide, yet 95% have no FDA-approved treatment. We need a bold new approach—and collaboration among all the stakeholders. The time to act is now.
I explain more in this editorial for @fortune.com: fortune.com/2025/03/10/r...
I explain more in this editorial for @fortune.com: fortune.com/2025/03/10/r...
Reposted
Looking forward to 𝗢𝗣𝗧 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟱, where Alltrna CTO William Kiesman will present on designing, manufacturing, and delivering #tRNA therapeutics for #StopCodonDisease. He will also join a breakout discussion on optimizing new RNA modalities as therapeutics.
bit.ly/41RGnAe
#RNAsky
bit.ly/41RGnAe
#RNAsky
March 10, 2025 at 2:30 PM
Looking forward to 𝗢𝗣𝗧 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟱, where Alltrna CTO William Kiesman will present on designing, manufacturing, and delivering #tRNA therapeutics for #StopCodonDisease. He will also join a breakout discussion on optimizing new RNA modalities as therapeutics.
bit.ly/41RGnAe
#RNAsky
bit.ly/41RGnAe
#RNAsky